GT
CRL icon

Greenleaf Trust’s Charles River Laboratories CRL Stock Holding History

Greenleaf Trust’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,051
Closed -$206K – 760
2023
Q3 		$206K Buy
1,051
+31
+3% +$6.36K ﹤0.01% 703
2023
Q2 		$214K Buy
+1,020
New +$203K ﹤0.01% 707
2022
Q1 		– Sell
-759
Closed -$286K – 764
2021
Q4 		$286K Sell
759
-64
-8% -$24.9K ﹤0.01% 615
2021
Q3 		$340K Buy
823
+74
+10% +$30.7K ﹤0.01% 528
2021
Q2 		$277K Buy
749
+30
+4% +$10K ﹤0.01% 605
2021
Q1 		$208K Buy
+719
New +$200K ﹤0.01% 679

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Greenleaf Trust's CRL Position: Q4 2023 in Review

Greenleaf Trust sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 1,051 shares — an estimated $206K sold.

Greenleaf Trust first reported a position in CRL in Q1 2021 and held it in 6 quarters. The position peaked at $340K in Q3 2021. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • Greenleaf Trust reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • Greenleaf Trust sold 1,051 Charles River Laboratories shares in Q4 2023, an estimated $206K.
  • Greenleaf Trust first reported a position in Charles River Laboratories in Q1 2021 and held it in 6 quarters.
  • Greenleaf Trust's Charles River Laboratories position peaked at $340K in Q3 2021.
  • 634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on Greenleaf Trust's 13F filing for Q4 2023, filed 31 Jan 2024.